Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KISS1R | Q969F8 | 5/20 | 0.64 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.62 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.61 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.61 |
| ▸ | NTSR2 | O95665 | 2/20 | 0.59 |
| ▸ | NTSR1 | P30989 | 2/20 | 0.59 |
| ▸ | TACR1 | P25103 | 1/20 | 0.59 |
| ▸ | NMBR | P28336 | 2/20 | 0.57 |
| ▸ | GRPR | P30550 | 2/20 | 0.57 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.57 |
| ▸ | GNRHR | P30968 | 1/20 | 0.56 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.56 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.56 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29598567 | 0.98 | KISS1R (0.65) | KISS1RC5AR1AGTR2AGTR1NTSR2 | |
| SCHEMBL34463648 | 0.93 | KISS1R (0.62) | KISS1RC5AR1AGTR2AGTR1NTSR2 | |
| SCHEMBL31331997 | 0.92 | KISS1R (0.62) | KISS1RC5AR1AGTR2AGTR1NTSR2 | |
| SCHEMBL29772142 | 0.91 | KISS1R (0.64) | KISS1RC5AR1AGTR2AGTR1NTSR2 | |
| SCHEMBL34470137 | 0.90 | KISS1R (0.67) | KISS1RC5AR1IL23R | |
| SCHEMBL30023454 | 0.89 | DPP3 (0.64) | KISS1RC5AR1IL23R | |
| Spinorphin SCHEMBL25217672 | 0.88 | KISS1R (0.60) | KISS1R | |
| Spinorphin SCHEMBL29977609 | 0.88 | KISS1R (0.60) | KISS1R | |
| Spinorphin SCHEMBL25273730 | 0.88 | KISS1R (0.60) | KISS1R | |
| SCHEMBL29894426 | 0.87 | NTSR1 (0.63) | AGTR2AGTR1NTSR2NTSR1SORT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121873174-A | Polypeptide composition with blood pressure reducing effect and preparation method and application thereof | 上海市第六人民医院金山分院(上海健康医学院附属金山区中心医院、上海市金山区中心医院) | 2026-04-17 | — | — | CN | disclosed |
| US-20240374689-A1 | HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME | LONGEVITY BIOTECH, INC. | 2024-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240374689-A1 | HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME | SCTR, GIPR, APLNR | KISS1R 1232/4885C5AR1 204/4885AGTR2 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.